Author of

• 20186

  +

  P3.07 - Immunology and Immunotherapy (ID 723)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Immunology and Immunotherapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 24117

    +

    P3.07-008 - Development of Immunomonitoring Assays for Dendritic Cell-Based Lung Cancer Immunotherapy (ID 9804)

    09:30 - 09:30  |  Author(s): L. Sadílková
    • Abstract
    • Slides

    Background:
    Allogeneic cancer cell lines might serve as a universal source of tumor antigens in the development of dendritic cell-based cancer vaccines. We showed that selected antigenic profile of lung cancer cell lines overlaps with antigenic profile of primary non/small cell lung cancer (NSCLC) tumors. However, it is unclear if T cells responses to all of these antigens can be detected in blood of NSCLC patients.
    
    Method:
    Peripheral blood mononuclear cells (PBMCs) of NSCL patients were stimulated and re-stimulated by commercially available mixes of antigenic peptides derived from these antigens over the course of 10 days. Tumor antigen-specific CD8[+] and CD4[+] T cells were characterized by IFN-γ production, granzyme B, perforin, an d CD137 or CD154 expression by flow cytometry. In addition, the expression of inhibitory molecules TIM3, CTLA-4, PD-1 and LAG-3 were evaluated on CD8[+] and CD4[+] T cells from PBMC of NSCLC patients. We further analysed 6 populations of myeloid-derived suppressor cells (MDCS) by a multicolor flow cytometry and their possible functional suppression by qPCR analysis of ARG1 and iNOS expression in PBMC and downregulation of CD3zξ in T cells from patient’s PBMCs compared to T cells from PBMCs of healthy donors.
    
    Result:
    We were able to detect tumor antigen-specific IFN-γ, Granzyme B and Perforin producing CD8[+] and CD4[+] T cells as well as expression of inhibitory molecules TIM3, CTLA-4, PD-1 and LAG-3. We were also able to detect populations of MDSCs in blood of NSCLC patients as well as healthy donors.
    
    Conclusion:
    This data will allow us to develop a protocol for immunomonitoring studies of the effectivity of dendritic cell-based lung cancer immunotherapy in ongoing phase I lung cancer clinical trial (NCT02470468).
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.